PREVENT（Warfarin）研究PPT课件.ppt

《PREVENT（Warfarin）研究PPT课件.ppt》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。

1、PreventionofRecurrentVenousThromboembolismNEnglJMedApr102003;348(15):1425-1434PREVENT(Warfarin)TrialWarfarin(targetINR,1.5-2.0)(n=255)Placebo(n=253)Endpoints(meanfollow-up2.1years):Primary–1)recurrentvenousthromboembolismand2)compositeofrecurrentvenousthromboembolism,ma

2、jorhemorrhage,ordeathPREVENTTrialNEnglJMedApr102003;348(15):1425-1434Open-labeltherapyfor28daysTodetermineifwarfarindosecouldbetitratedtoanINRof1.5to2.0withoutexceeding10mgperdayToseeifpatientscouldmaintainacomplianceof85%508patientswithdocumentedidiopathicvenousthrombo

3、embolism,>3uninterruptedmonthsoforalanticoagulationtherapywithfull-dosewarfarinAge>30yearsPREVENTTrial:CompositeEndpointPlaceboNEnglJMedApr102003;348(15):1425-1434Compositeofrecurrentthromboembolism,majorbleedanddeathCompositeEndpointHR=0.52,p=0.01Trialdiscontinuedearly

4、bytheDSMB,duetoalarge,significantbenefitwithlow-intensitywarfarintherapyandtheabsenceofanysubstantialevidenceofanysignificantuntowardsideeffectsWarfarinPREVENTTrialNEnglJMedApr102003;348(15):1425-1434WarfarinPlaceboRecurrentVenousThromboembolismHR=0.36,p<0.001WarfarinPl

5、aceboAll-CauseMortalityHR=0.50,p=0.26PREVENT:ConclusionsAmongpatientswithidiopathicvenousthromboembolismwhohadreceivedfull-doseanticoagulationtherapyforsixmonths,treatmentwithlow-intensitywarfarin(targetINR,1.5-2.0)wasassociatedwithareductioninrecurrentvenousthromboembo

6、lismandinthecompositeofrecurrentvenousthromboembolism,majorhemorrhage,ordeathduringfollow-upNosignificantexcessmajorbleedingoccurredinthewarfarinarmFirstrandomizedtrialtoexaminetheuseoflow-intensitywarfarintherapy,ratherthanfull-dosetherapyinthispopulation